Cooperative behaviour and phenotype plasticity evolve during melanoma progression

Abstract A major challenge for managing melanoma is its tumour heterogeneity based on individual co‐existing melanoma cell phenotypes. These phenotypes display variable responses to standard therapies, and they drive individual steps of melanoma progression; hence, understanding their behaviour is imperative. Melanoma phenotypes are defined by distinct transcriptional states, which relate to different melanocyte lineage development phases, ranging from a mesenchymal, neural crest‐like to a proliferative, melanocytic phenotype. It is thought that adaptive phenotype plasticity based on transcriptional reprogramming drives melanoma progression, but at which stage individual phenotypes dominate and moreover, how they interact is poorly understood. We monitored melanocytic and mesenchymal phenotypes throughout melanoma progression and detected transcriptional reprogramming at different stages, with a gain in mesenchymal traits in circulating melanoma cells (CTCs) and proliferative features in metastatic tumours. Intriguingly, we found that distinct phenotype populations interact in a cooperative manner, which generates tumours of greater “fitness,” supports CTCs and expands organotropic cues in metastases. Fibronectin, expressed in mesenchymal cells, acts as key player in cooperativity and promotes survival of melanocytic cells. Our data reveal an important role for inter‐phenotype communications at various stages of disease progression, suggesting these communications could act as therapeutic target.

[1]  C. Wellbrock,et al.  Phenotype plasticity as enabler of melanoma progression and therapy resistance , 2019, Nature Reviews Cancer.

[2]  K. Flaherty,et al.  Toward Minimal Residual Disease-Directed Therapy in Melanoma , 2018, Cell.

[3]  T. Graeber,et al.  Multi-stage Differentiation Defines Melanoma Subtypes with Differential Vulnerability to Drug-Induced Iron-Dependent Oxidative Stress. , 2018, Cancer cell.

[4]  T. Voet,et al.  Identification of the tumour transition states occurring during EMT , 2018, Nature.

[5]  C. Wellbrock,et al.  Collagen abundance controls melanoma phenotypes through lineage-specific microenvironment sensing , 2018, Oncogene.

[6]  F. Al-Ejeh,et al.  MITF and BRN2 contribute to metastatic growth after dissemination of melanoma , 2017, Scientific Reports.

[7]  D. Lipsker,et al.  MITF-High and MITF-Low Cells and a Novel Subpopulation Expressing Genes of Both Cell States Contribute to Intra- and Intertumoral Heterogeneity of Primary Melanoma , 2017, Clinical Cancer Research.

[8]  Reinhard Dummer,et al.  Targeting endothelin receptor signalling overcomes heterogeneity driven therapy failure , 2017, EMBO molecular medicine.

[9]  A. Orlandi,et al.  Minimal residual disease in melanoma: circulating melanoma cells and predictive role of MCAM/MUC18/MelCAM/CD146 , 2017, Cell Death Discovery.

[10]  Charles H. Yoon,et al.  Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq , 2016, Science.

[11]  J. Mesirov,et al.  The Molecular Signatures Database Hallmark Gene Set Collection , 2015 .

[12]  D. Gautheret,et al.  New Functional Signatures for Understanding Melanoma Biology from Tumor Cell Lineage-Specific Analysis , 2015, Cell reports.

[13]  Nam Huh,et al.  Phylogenetic analyses of melanoma reveal complex patterns of metastatic dissemination , 2015, Proceedings of the National Academy of Sciences.

[14]  K. Polyak,et al.  Tumorigenesis: it takes a village , 2015, Nature Reviews Cancer.

[15]  M. Ringnér,et al.  Genome-Wide DNA Methylation Analysis in Melanoma Reveals the Importance of CpG Methylation in MITF Regulation. , 2015, The Journal of investigative dermatology.

[16]  V. Prod’homme,et al.  Tumour-derived SPARC drives vascular permeability and extravasation through endothelial VCAM1 signalling to promote metastasis , 2015, Nature Communications.

[17]  C. Wellbrock,et al.  Microphthalmia‐associated transcription factor in melanoma development and MAP‐kinase pathway targeted therapy , 2015, Pigment cell & melanoma research.

[18]  S. Aerts,et al.  Decoding the regulatory landscape of melanoma reveals TEADS as regulators of the invasive cell state , 2015, Nature Communications.

[19]  J. Massagué,et al.  Therapy-induced tumour secretomes promote resistance and tumour progression , 2015, Nature.

[20]  Sridhar Ramaswamy,et al.  Circulating Tumor Cell Clusters Are Oligoclonal Precursors of Breast Cancer Metastasis , 2014, Cell.

[21]  C. Wellbrock,et al.  Heterogeneous Tumor Subpopulations Cooperate to Drive Invasion , 2014, Cell reports.

[22]  K. Polyak,et al.  Non-cell autonomous tumor-growth driving supports sub-clonal heterogeneity , 2014, Nature.

[23]  P. Lorigan,et al.  Prevalence and heterogeneity of circulating tumour cells in metastatic cutaneous melanoma , 2014, Melanoma research.

[24]  J. Lachuer,et al.  A switch in the expression of embryonic EMT-inducers drives the development of malignant melanoma. , 2013, Cancer cell.

[25]  A. Marx,et al.  Circulating fibronectin controls tumor growth. , 2013, Neoplasia.

[26]  L. Chin,et al.  HOXA1 drives melanoma tumor growth and metastasis and elicits an invasion gene expression signature that prognosticates clinical outcome , 2013, Oncogene.

[27]  Sridhar Ramaswamy,et al.  RNA sequencing of pancreatic circulating tumour cells implicates WNT signaling in metastasis , 2012, Nature.

[28]  R. Dummer,et al.  Systematic classification of melanoma cells by phenotype‐specific gene expression mapping , 2012, Pigment cell & melanoma research.

[29]  R. Dummer,et al.  In melanoma, beta-catenin is a suppressor of invasion. , 2011, Oncogene.

[30]  K. Bille,et al.  Senescent cells develop a PARP-1 and nuclear factor-{kappa}B-associated secretome (PNAS). , 2011, Genes & development.

[31]  P. Bahadoran,et al.  Mitf is the key molecular switch between mouse or human melanoma initiating cells and their differentiated progeny , 2011, Oncogene.

[32]  C. Bertolotto,et al.  Essential role of microphthalmia transcription factor for DNA replication, mitosis and genomic stability in melanoma , 2011, Oncogene.

[33]  A. Berns,et al.  A functional role for tumor cell heterogeneity in a mouse model of small cell lung cancer. , 2011, Cancer cell.

[34]  M. Herlyn,et al.  Tenascin-C promotes melanoma progression by maintaining the ABCB5-positive side population , 2010, Oncogene.

[35]  R. Dhir,et al.  Plasma fibronectin promotes lung metastasis by contributions to fibrin clots and tumor cell invasion. , 2010, Cancer research.

[36]  A. Balmain,et al.  Guidelines for the welfare and use of animals in cancer research , 2010, British Journal of Cancer.

[37]  P. Foubert,et al.  Integrin α4β1 Signaling Is Required for Lymphangiogenesis and Tumor Metastasis , 2010 .

[38]  C. Bertolotto,et al.  Fifteen‐year quest for microphthalmia‐associated transcription factor target genes , 2010, Pigment cell & melanoma research.

[39]  L. Pearl,et al.  NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis. , 2008, Cancer research.

[40]  R. Dummer,et al.  In vivo switching of human melanoma cells between proliferative and invasive states. , 2008, Cancer research.

[41]  Jane Goodall,et al.  Mitf regulation of Dia1 controls melanoma proliferation and invasiveness. , 2006, Genes & development.

[42]  A. Aplin,et al.  B-RAF and PI-3 kinase signaling protect melanoma cells from anoikis , 2006, Oncogene.

[43]  R. Marais,et al.  Elevated expression of MITF counteracts B-RAF–stimulated melanocyte and melanoma cell proliferation , 2005, The Journal of cell biology.

[44]  Suyun Huang,et al.  Fully human antibodies to MCAM/MUC18 inhibit tumor growth and metastasis of human melanoma. , 2002, Cancer research.

[45]  G. Ghanem,et al.  Transcriptional repression of the microphthalmia gene in melanoma cells correlates with the unresponsiveness of target genes to ectopic microphthalmia-associated transcription factor. , 2001, The Journal of investigative dermatology.

[46]  M. Schartl,et al.  Activation of phosphatidylinositol 3-kinase by a complex of p59fyn and the receptor tyrosine kinase Xmrk is involved in malignant transformation of pigment cells. , 2000, European journal of biochemistry.

[47]  Virgil L. Woods,et al.  A polymeric form of fibronectin has antimetastatic effects against multiple tumor types , 1996, Nature Medicine.

[48]  A. Orlandi,et al.  Minimal residual disease in melanoma : circulating melanoma cells and predictive role of MCAM / MUC 18 / MelCAM / CD 146 , 2017 .

[49]  J. Mesirov,et al.  The Molecular Signatures Database (MSigDB) hallmark gene set collection. , 2015, Cell systems.